Literature DB >> 9661074

Mice lacking osteopontin show normal development and bone structure but display altered osteoclast formation in vitro.

S R Rittling1, H N Matsumoto, M D McKee, A Nanci, X R An, K E Novick, A J Kowalski, M Noda, D T Denhardt.   

Abstract

We have used homologous recombination in embryonic stem cells to generate mice with a targeted disruption of the osteopontin (Opn, or Spp1, for secreted phosphoprotein 1) gene. Mice homozygous for this disruption fail to express osteopontin (OPN) as assessed at both the mRNA and protein level, although an N-terminal fragment of OPN is detectable at extremely low levels in the bones of -/- animals. The Opn -/- mice are fertile, their litter size is normal, and they develop normally. The bones and teeth of animals not expressing OPN are morphologically normal at the level of light and electron microscopy, and the skeletal structure of young animals is normal as assessed by radiography. Ultrastructurally, proteinaceous structures normally rich in OPN, such as cement lines, persist in the bones of the Opn-/- animals. Osteoclastogenesis was assessed in vitro in cocultures with a feeder layer of calvarial osteoblast cells from wild-type mice. Spleen cells from Opn-/- mice cells formed osteoclasts 3- to 13-fold more frequently than did control Opn+/+ cells, while the extent of osteoclast development from Opn -/- bone marrow cells was about 2- to 4-fold more than from the corresponding wild-type cells. Osteoclast development occurred when Opn-/- spleen cells were differentiated in the presence of Opn-/-osteoblasts, indicating that endogenous OPN is not required for this process. These results suggest that OPN is not essential for normal mouse development and osteogenesis, but can modulate osteoclast differentiation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9661074     DOI: 10.1359/jbmr.1998.13.7.1101

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  135 in total

Review 1.  Vascular calcification and its relation to bone calcification: possible underlying mechanisms.

Authors:  Nilam Mody; Yin Tintut; Kristen Radcliff; Linda L Demer
Journal:  J Nucl Cardiol       Date:  2003 Mar-Apr       Impact factor: 5.952

2.  Osteopontin inhibits mineral deposition and promotes regression of ectopic calcification.

Authors:  Susan A Steitz; Mei Y Speer; Marc D McKee; Lucy Liaw; Manuela Almeida; Hsueh Yang; Cecilia M Giachelli
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

3.  Osteopontin deficiency enhances parathyroid hormone/ parathyroid hormone related peptide receptor (PPR) signaling-induced alteration in tooth formation and odontoblastic morphology.

Authors:  Maki Morishita; Noriaki Ono; Kentano Miyai; Tomomi Nakagawa; Ryo Hanyu; Masashi Nagao; Paksinee Kamolratanakul; Takuya Notomi; Susan R Rittling; David T Denhardt; Henry M Kronenberg; Yoichi Ezura; Tadayoshi Hayata; Tetsuya Nakamoto; Masaki Noda
Journal:  Tissue Cell       Date:  2011-04-21       Impact factor: 2.466

Review 4.  Matrix proteins.

Authors:  Caren M Gundberg
Journal:  Osteoporos Int       Date:  2003-08-29       Impact factor: 4.507

Review 5.  Intracellular osteopontin (iOPN) and immunity.

Authors:  Makoto Inoue; Mari L Shinohara
Journal:  Immunol Res       Date:  2011-04       Impact factor: 2.829

6.  Osteopontin is up-regulated and associated with neutrophil and macrophage infiltration in glioblastoma.

Authors:  Nadia A Atai; Manju Bansal; Cheungh Lo; Joost Bosman; Wikky Tigchelaar; Klazien S Bosch; Ard Jonker; Philip C De Witt Hamer; Dirk Troost; Christopher A McCulloch; Vincent Everts; Cornelis J F Van Noorden; Jaro Sodek
Journal:  Immunology       Date:  2010-08-17       Impact factor: 7.397

Review 7.  Apolipoprotein D.

Authors:  Eric Rassart; Frederik Desmarais; Ouafa Najyb; Karl-F Bergeron; Catherine Mounier
Journal:  Gene       Date:  2020-06-15       Impact factor: 3.688

8.  Osteopontin regulates dentin and alveolar bone development and mineralization.

Authors:  B L Foster; M Ao; C R Salmon; M B Chavez; T N Kolli; A B Tran; E Y Chu; K R Kantovitz; M Yadav; S Narisawa; J L Millán; F H Nociti; M J Somerman
Journal:  Bone       Date:  2017-12-05       Impact factor: 4.398

Review 9.  Matricellular proteins in cardiac adaptation and disease.

Authors:  Nikolaos G Frangogiannis
Journal:  Physiol Rev       Date:  2012-04       Impact factor: 37.312

Review 10.  Effects of bone matrix proteins on fracture and fragility in osteoporosis.

Authors:  Grażyna E Sroga; Deepak Vashishth
Journal:  Curr Osteoporos Rep       Date:  2012-06       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.